Alemtuzumab

Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more...


The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with...


New magnetic resonance imaging ( MRI ) data from the Lemtrada ( Alemtuzumab ) clinical development program were presented at...


Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented...


Alemtuzumab ( Lemtrada ), an anti-CD52 monoclonal antibody, has increased the risk of thyroid dysfunction in CAMMS223, a phase 2...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after...


The results from the Lemtrada ( Alemtuzumab ) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple...


According to NICE ( National Institute for Health and Clinical Excellence ) Ofatumumab ( Arzerra ) is not recommended for...


GlaxoSmithKline ( GSK ) and Genmab have announced the results from the concluded pivotal trial of Ofatumumab ( Arzerra )...


Genzyme Europe BV has informed Healthcare Professional of six infection-related deaths, reported from a trial ( CALGB10101 ) in which...


Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath (...


The study enrolled patients with chronic lymphocytic leukemia ( CLL ), heavily pre-treated, who did not respond to, or who...


Genzyme Europe BV has informed Healthcare Professional of six infection-related deaths, reported from a trial ( CALGB10101 ) in which...


Bayer Schering Pharma AG and Genzyme Europe BV have informed Healthcare Professionals on six infection-related deaths, reported from a trial (...


Two-year interim results from a Phase 2 trial comparing MabCampath ( Alemtuzumab; Campath ) with Rebif ( Interferon beta-1a )...


The FDA ( Food and Drug Administration ) has learned of three patients with multiple sclerosis who have developed severe...


The 84 percent of patients who had no detectable traces of chronic lymphocytic leukemia ( CLL ) after receiving Alemtuzumab...